In 2005, CDC published guidelines for using the QuantiFERON-TB Gold test (QFT-
G)(Cellestis Limited, Carnegie, Victoria, Australia)(CDC. Guidelines for using the …

Interferon-γ release assays (IGRAs) are now established for the immunodiagnosis of latent
infection with Mycobacterium tuberculosis in many countries. However, the role of IGRAs for …

Background The clinical utility of interferon-γ release assays (IGRAs) for diagnosis of active
tuberculosis is unclear, although they are commonly used in countries with a low incidence …

The sensitivities of various gamma interferon release assays (IGRAs) for the detection of
past latent Mycobacterium tuberculosis infection are not known. In this study, we aimed to …

Background Interferon-gamma release assays (IGRAs) have provided a new method for the
diagnosis of Mycobacterium tuberculosis infection. However, the role of IGRAs for the …

Background. Interferon-γ release assays (IGRAs) are attractive alternatives to the tuberculin
skin test (TST) for detecting Mycobacterium tuberculosis infection. However, the inability to …

Interferon-gamma release assays (IGRAs) provide a new diagnostic method for
Mycobacterium tuberculosis (TB) infection. However, the diagnostic value of IGRAs for …

Summary On May 2, 2005, a new in vitro test, QuantiFERON®-TB Gold (QFT-G, Cellestis
Limited, Carnegie, Victoria, Australia), received final approval from the US Food and Drug …

Rationale: Although IFN-γ release assays (IGRAs) are widely used to screen for
Mycobacterium tuberculosis infection in high-income countries, published data on …

Background: Interferon-γ–release assays (IGRAs) are alternatives to the tuberculin skin test
(TST). A recent meta-analysis showed that IGRAs have high specificity, even among …